# Syndax Pharmaceuticals Inc (SNDX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Syndax Pharmaceuticals Inc's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/SNDX/mda/fy2025/): filed 2026-02-26; accession 0001193125-26-076536 (https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/SNDX/mda/fy2024/): filed 2025-03-03; accession 0000950170-25-030394 (https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm)
- [FY 2023 MD&A](/company/SNDX/mda/fy2023/): filed 2024-02-27; accession 0000950170-24-021253 (https://www.sec.gov/Archives/edgar/data/1395937/000095017024021253/sndx-20231231.htm)
- [FY 2022 MD&A](/company/SNDX/mda/fy2022/): filed 2023-02-28; accession 0000950170-23-005079 (https://www.sec.gov/Archives/edgar/data/1395937/000095017023005079/sndx-20221231.htm)
- [FY 2021 MD&A](/company/SNDX/mda/fy2021/): filed 2022-03-01; accession 0001564590-22-008112 (https://www.sec.gov/Archives/edgar/data/1395937/000156459022008112/sndx-10k_20211231.htm)

Back to /company/SNDX/